Barclays analyst Matt Miksic raised the firm’s price target on Johnson & Johnson to $176 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. The firm says the company’s sales and earnings beat on execution and currency.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Stock (JNJ) Gets a Price Target Boost by Stifel’s Analyst Post Q2 Earnings Beat
- Johnson & Johnson Reports Strong Quarterly Growth
- Johnson & Johnson: Strong Performance Overshadowed by Biosimilar Competition and Litigation Risks
- Johnson & Johnson price target raised to $176 from $171 at Morgan Stanley
- Johnson & Johnson delivered ‘solid’ Q2, says Wells Fargo